Fayez Sarofim & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-30,329
| Closed | -$3.09M | – | 300 |
|
|
2023
Q2 | $3.09M | Hold |
30,329
| – | – | 0.01% | 125 |
|
|
2023
Q1 | $2.76M | Hold |
30,329
| – | – | 0.01% | 129 |
|
|
2022
Q4 | $1.15M | Hold |
30,329
| – | – | ﹤0.01% | 168 |
|
|
2022
Q3 | $762K | Hold |
30,329
| – | – | ﹤0.01% | 188 |
|
|
2022
Q2 | $922K | Hold |
30,329
| – | – | ﹤0.01% | 191 |
|
|
2022
Q1 | $994K | Hold |
30,329
| – | – | ﹤0.01% | 199 |
|
|
2021
Q4 | $800K | Buy |
30,329
+200
| +0.7% | +$5.28K | ﹤0.01% | 224 |
|
|
2021
Q3 | $3.03M | Hold |
30,129
| – | – | 0.01% | 135 |
|
|
2021
Q2 | $4.26M | Hold |
30,129
| – | – | 0.01% | 125 |
|
|
2021
Q1 | $3M | Hold |
30,129
| – | – | 0.01% | 130 |
|
|
2020
Q4 | $3.73M | Hold |
30,129
| – | – | 0.01% | 118 |
|
|
2020
Q3 | $2.94M | Hold |
30,129
| – | – | 0.01% | 121 |
|
|
2020
Q2 | $4.7M | Hold |
30,129
| – | – | 0.02% | 102 |
|
|
2020
Q1 | $4.35M | Hold |
30,129
| – | – | 0.03% | 97 |
|
|
2019
Q4 | $6.16M | Hold |
30,129
| – | – | 0.03% | 101 |
|
|
2019
Q3 | $2.42M | Hold |
30,129
| – | – | 0.01% | 124 |
|
|
2019
Q2 | $2.84M | Hold |
30,129
| – | – | 0.01% | 121 |
|
|
2019
Q1 | $2.58M | Hold |
30,129
| – | – | 0.01% | 127 |
|
|
2018
Q4 | $1.69M | Hold |
30,129
| – | – | 0.01% | 132 |
|
|
2018
Q3 | $2.46M | Hold |
30,129
| – | – | 0.01% | 125 |
|
|
2018
Q2 | $1.05M | Buy |
+30,129
| New | +$1.05M | 0.01% | 158 |
|